Search
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnThe European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.
Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10793ApprovedInvestigationalIn contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Mixtures: FLUARIX TETRA SUSPENSION FOR INJECTION, Influvac Tetra, suspension for injection in pre-filled syringeGlimepiride
go.drugbank.com/drugs/DB00222ApprovedInvestigationalSulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. … [A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM.
Phenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedIt is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.
Categories: Agents for Dermatitis, Excluding CorticosteroidsTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalIt is also being investigated for the combination use with other chemotherapeutic agents for recurrent or metastatic cervical cancer.[A238924] … This is the first and only approved antibody-drug conjugate for this therapeutic indication.
Travoprost
go.drugbank.com/drugs/DB00287ApprovedInvestigationalUnlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced risk for
Gefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse. … Through enhancing osteogenesis at the site of implantation, dibotermin alfa accelerates the healing of open tibial shaft fractures and reduces the need for secondary intervention [A31945].
Categories: Drugs for Treatment of Bone DiseasesAcoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. … [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis.